Trial · NCT03444870
Results by group97
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 97
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB | Global - DBT Period: Placebo | 3.65 | Standard Error 0.16 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB | Global - DBT Period: Gantenerumab | 3.35 | Standard Error 0.14 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score | Global - DBT Period: Placebo | 9.82 | Standard Error 0.57 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score | Global - DBT Period: Gantenerumab | 8.57 | Standard Error 0.47 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score | Global - DBT Period: Placebo | -12.32 | Standard Error 0.68 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score | Global - DBT Period: Gantenerumab | -11.21 | Standard Error 0.60 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score | Global - DBT Period: Placebo | 8.13 | Standard Error 0.33 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score | Global - DBT Period: Gantenerumab | 7.28 | Standard Error 0.30 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score | Global - DBT Period: Placebo | -5.18 | Standard Error 0.25 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score | Global - DBT Period: Gantenerumab | -4.86 | Standard Error 0.23 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score | Global - DBT Period: Placebo | 8.42 | Standard Error 0.52 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score | Global - DBT Period: Gantenerumab | 7.44 | Standard Error 0.43 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score | Global - DBT Period: Placebo | -3.46 | Standard Error 0.31 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score | Global - DBT Period: Gantenerumab | -3.53 | Standard Error 0.30 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest | Global - DBT Period: Placebo | -6.47 | Standard Error 0.64 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest | Global - DBT Period: Gantenerumab | -6.27 | Standard Error 0.54 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score | Global - DBT Period: Placebo | -10.80 | Standard Error 0.56 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score | Global - DBT Period: Gantenerumab | -9.80 | Standard Error 0.51 | score on a scale | |
| DBT Period: Number of Participants With at Least One Adverse Event (AE) | Global - DBT Period: Placebo | 423 | Participants | ||
| DBT Period: Number of Participants With at Least One Adverse Event (AE) | Global - DBT Period: Gantenerumab | 454 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03444870/results